Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Vik Chopra
BMO

Vik Chopra

BMO Capital
Wall Street Analyst
★★★★☆
#640
on 13Foresight · ranked by our own returns
61%
Success Rate
+3.1%
Average Return
41 of 67 calls profitable · +11.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 61% of Vik Chopra's ratings turned a profit when each position was held for 1 year — averaging +3.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

35 Buy 35 Hold 0 Sell
Vik's Stock Coverage 18 ratings · 2026-11-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SYK
Stryker
 Oct 30, 2026 BUY Strong Buy
+18.5% avg upside
38 analysts
$309.00
5.96% Upside
 +11.1% ·
ATEC
Alphatec Holdings
 Oct 30, 2026 HOLD Strong Buy
+116.9% avg upside
23 analysts
$8.00
13.55% Upside
 +5.7% ·
GEHC
GE Healthcare Technologies Inc
 Oct 29, 2026 HOLD Strong Buy
+10.2% avg upside
23 analysts
$75.00
2.09% Downside
 +7.1% ·
CNMD
Conmed
 Oct 28, 2026 HOLD Hold
+48.7% avg upside
12 analysts
$45.00
1.51% Upside
 +12.5% ·
ALGN
Align Tech
 Oct 28, 2026 BUY Buy
+89.9% avg upside
21 analysts
$199.00
32.79% Upside
 +9.7% ·
IART
Integra Lifesciences
 Oct 22, 2026 HOLD Buy
+208.1% avg upside
22 analysts
$14.00
9.81% Upside
 +17.8% ·
ISRG
Intuitive Surgical
 Oct 20, 2026 BUY Strong Buy
+12.0% avg upside
37 analysts
$518.00
20.00% Upside
 +0.4% ·
NVST
Envista Holdings
 Sep 28, 2026 HOLD Buy
+27.4% avg upside
19 analysts
$26.00
10.62% Upside
 +7.4% ·
XRAY
DENTSPLY SIRONA
 Sep 16, 2026 HOLD Buy
+182.3% avg upside
25 analysts
$10.00
4.90% Upside
 -6.9% ·
ENOV
Enovis
 Sep 01, 2026 BUY Strong Buy
+226.7% avg upside
39 analysts
$27.00
35.65% Upside
 +39.1% ·
GMED
Globus Medical
 Aug 27, 2026 BUY Strong Buy
+18.8% avg upside
24 analysts
$94.00
20.41% Upside
 -12.3% ·
SOLV
Solventum Corporation
 Aug 17, 2026 HOLD Buy
+12.8% avg upside
16 analysts
$84.00
3.31% Upside
 +2.5% ·
ZBH
Zimmer Biomet Holdings
 Aug 06, 2026 HOLD Buy
+20.5% avg upside
39 analysts
$96.00
1.65% Upside
 +8.7% ·
HSIC
Henry Schein
 Aug 04, 2026 HOLD Buy
+9.6% avg upside
25 analysts
$85.00
0.22% Upside
 -0.8% ·
TFX
Teleflex
 Jul 09, 2026 BUY Buy
+31.3% avg upside
20 analysts
$159.00
13.68% Upside
 +15.7% ·
CH:STMN
Straumann Holding AG
 Jul 09, 2026 BUY Strong Buy
+32.7% avg upside
15 analysts
 — -0.7% ·
NPCE
NeuroPace
 Mar 06, 2026 BUY Strong Buy
+46.9% avg upside
14 analysts
$19.00
54.51% Upside
 -10.9% ·
EW
Edwards Lifesciences
 Mar 21, 2016 BUY Strong Buy
+10.0% avg upside
35 analysts
$109.00
18.40% Upside
 +8.4% ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Vik Chopra — Frequently Asked Questions
How accurate are Vik Chopra's stock ratings?
Based on the calls 13Foresight could measure, about 61% of Vik's ratings were profitable over a one-year hold, with an average return of +3.2% per rating, or +0.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Vik ranked on 13Foresight?
Vik Chopra is currently ranked #640 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Vik cover?
Vik most recently has ratings on SYK, ATEC, GEHC, CNMD, ALGN, IART, ISRG, NVST, XRAY, ENOV, GMED, SOLV and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.